Regardless, in both the HMA-Ven [25] and IDH2 inhibitor [37] treatment trials in MPN-BP/AP, morphologic and molecular evidence of chronic phase disease persisted despite the achievement of CR. Here, IDH2 is linked to myeloproliferative neoplasm.